Lilly's $3.25B buyout ends Kelonia's cash struggles

Source: statnews.com

TL;DR

The story at a glance

Eli Lilly announced its $3.25 billion acquisition of Kelonia Therapeutics, a Boston-based biotech developing in vivo cell therapies for cancer like multiple myeloma and autoimmune diseases. Venrock partner Bryan Roberts shared details on Kelonia's cash struggles after incubating the startup, originally called Elcano Therapeutics. The article, timed with Monday's deal announcement, includes the original 2020 investment memo and slide deck for a rare view into early biotech decisions. This comes as Lilly expands its oncology pipeline with Kelonia's lentiviral gene delivery platform.[[1]](https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/)[[2]](https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19)[[3]](https://keloniatx.com/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies)

Key points

Details and context

Kelonia's platform uses engineered lentiviral particles for targeted in vivo gene delivery to T-cells, aiming to simplify CAR-T production versus ex vivo methods that require cell extraction, modification, and reinfusion. This could lower costs and broaden access for blood cancers and beyond, per company statements reported alongside the deal.[[3]](https://keloniatx.com/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies)[[5]](https://www.fiercebiotech.com/biotech/lilly-picks-another-vivo-car-t-company-7b-deal-kelonia)

The startup launched publicly in 2022 after Venrock incubation, focusing initially on hematologic cancers. Early Phase 1 data for KLN-1010 from 2025 ASH showed promising tolerability and responses in small multiple myeloma patient group, validating the approach per Lilly executives.[[5]](https://www.fiercebiotech.com/biotech/lilly-picks-another-vivo-car-t-company-7b-deal-kelonia)

Venrock's memo highlighted potential in cell-type-specific gene therapy as the next wave after viral therapies, positioning early Kelonia amid many competing efforts.[[7]](https://oncodaily.com/techology/kelonia-487928)

Key quotes

“Three times, the company came within a week of running out of cash,” according to Bryan Roberts, partner at Venrock, which incubated the biotech.[[1]](https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/)

Why it matters

Lilly gains a platform to simplify cell therapies, potentially expanding treatments for multiple myeloma and other diseases beyond current ex vivo limits. Investors and biotech founders see a model of survival through near-failures leading to high-value exit, while patients could benefit from off-the-shelf options if milestones hit. Watch Phase 1 readouts for KLN-1010 and deal close in late 2026, as regulatory hurdles could affect milestone payouts.[[2]](https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19)

What changed

Kelonia operated independently on $60 million funding, repeatedly nearing shutdown. Lilly's acquisition provides $3.25 billion upfront plus milestones, securing its future. Deal announced April 20, 2026.[[1]](https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/)[[2]](https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19)

FAQ

Q: What is Kelonia Therapeutics developing?

A: Cell therapies using in vivo gene delivery via lentiviral vectors to create CAR-T cells inside the body for cancer like multiple myeloma and autoimmune diseases. Its lead, KLN-1010, targets BCMA in Phase 1 for relapsed/refractory multiple myeloma. Early data showed good tolerability.[[1]](https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/)[[3]](https://keloniatx.com/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies)

Q: How did Kelonia fund its operations before the acquisition?

A: Raised about $60 million over five years from investors including Venrock, which incubated it as Elcano in 2020; this included a $50 million Series A in 2022. The company faced three near-cashouts within a week each.[[1]](https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/)[[6]](http://keloniatx.com/kelonia-therapeutics-launches-with-50-million-series-a-financing-to-pioneer-precision-targeted-genetic-medicines)

Q: What do the slide deck and memo reveal?

A: They are Venrock's original November 2020 documents for launching Elcano (now Kelonia), assessing gene therapy landscape and rationale for investing in cell-type-specific targeting amid many competitors.[[1]](https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/)[[7]](https://oncodaily.com/techology/kelonia-487928)

Q: When is the Lilly-Kelonia deal expected to close?

A: Second half of 2026, pending regulatory approvals and customary conditions. Upfront payment goes immediately upon close, with rest on milestones.[[2]](https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19)